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Duck is susceptible to many pathogens, such as duck hepatitis virus, duck enteritis virus (DEV), duck tembusu virus,
H5N1 highly pathogenic avian influenza virus (HPAIV) in particular. With the significant role of duck in the evolution
of H5N1 HPAIV, control and eradication of H5N1 HPAIV in duck through vaccine immunization is considered an
effective method in minimizing the threat of a pandemic outbreak. Consequently, a practical strategy to construct a
vaccine against these pathogens should be determined. In this study, the DEV was examined as a candidate
vaccine vector to deliver the hemagglutinin (HA) gene of H5N1, and its potential as a polyvalent vaccine was
evaluated. A modified mini-F vector was inserted into the gB and UL26 gene junction of the attenuated DEV vaccine
strain C-KCE genome to generate an infectious bacterial artificial chromosome (BAC) of C-KCE (vBAC-C-KCE). The HA
gene of A/duck/Hubei/xn/2007 (H5N1) was inserted into the C-KCE genome via the mating-assisted genetically
integrated cloning (MAGIC) to generate the recombinant vector pBAC-C-KCE-HA. A bivalent vaccine C-KCE-HA
was developed by eliminating the BAC backbone. Ducks immunized with C-KCE-HA induced both the cross-reactive
antibodies and T cell response against H5. Moreover, C-KCE-HA-immunized ducks provided rapid and long-lasting
protection against homologous and heterologous HPAIV H5N1 and DEV clinical signs, death, and primary viral
replication. In conclusion, our BAC-C-KCE is a promising platform for developing a polyvalent live attenuated vaccine.Introduction
Ducks are considered one of the most important water-
fowl for its various usages in different aspects. In China
and southeast Asia, duck farming is not only a trad-
itional agribusiness for nourishment, but also critical for
habiliment. However, this traditional business is ser-
iously threatened by numerous pathogens, such as avian
influenza virus (AIV), duck hepatitis virus, duck enteritis
virus (DEV), and duck tembusu virus [1,2].
Waterfowl is considered a larger and key natural reservoir
of influenza A viruses. It is currently known that almost all
the subtypes can be isolated from waterfowl with the* Correspondence: jml8328@126.com
†Equal contributors
1State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural
University, Wuhan 430070, China
2College of Veterinary Medicine, Huazhong Agricultural University, Wuhan
430070, China
Full list of author information is available at the end of the article
© 2015 Zou et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.exception of the H13 and H16 subtypes [3-5]. Notably,
a novel reassorting avian-origin influenza A (H7N9)
virus has been isolated from the ducks of live poultry
markets [6]. As of October 25, 2013, the virus had
caused 137 human cases and 45 human deaths during
both epidemic waves in China [7]. The highly patho-
genic avian influenza virus (HPAIV) H5N1 is a poten-
tial pandemic threat that has caused global concern in
many Asian countries, and the duck is believed to be
the primary source of infection [2]. Since 2003, a total
of 694 human beings have been infected with HPAIV
H5N1, with fatality rates approaching 60% [8]. Although
many measures have been taken to control AIV infection
and transmission, AIV is still a huge threat to public
health and the duck industry.
Under these circumstances, vaccination, as an adjunct
for improving bio-security and stamping-out policies, con-
tributes to protecting ducks against AIV infection [9].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zou et al. Veterinary Research  (2015) 46:42 Page 2 of 15Currently, conventional inactivated vaccines are largely
used for routine preventative vaccination and target
vaccination programs [10]. However, inactivated vac-
cine production is costly and time-consuming, and the oil
emulsion adjuvant can cause severe adverse reactions [11].
Furthermore, the risk of contamination by avian patho-
gens in the egg supply or microbial contaminants during
processing has previously jeopardized vaccine supplies
[12]. Additionally, inactivated vaccines usually need
several weeks to provide solid immune protection [13],
which is a major limitation in emergency vaccination
to establish a buffer zone. Considering the drawbacks
aforementioned, alternative vaccine manufacturing strat-
egies are needed.
Duck viral enteritis is caused by the DEV which belongs
to Anatid herpesvirus 1; it is an acute, contagious, and
lethal disease of ducks, geese, and swans [14]. The
DEV genome consists of approximately 160 kilobase
pairs (kbp), each pair is composed of two unique sequences,
unique long (UL) and unique short (US). The latter is
flanked by inverted repeated sequences (IRS and TRS) [15].
A live C-KCE vaccine strain attenuated in the embryonated
chicken egg has been developed and utilized to control duck
viral enteritis for many years. Furthermore, the ability to
induce DEV immunity is not significantly interfered by
pre-existing antibodies [16]. Additionally, DEV pos-
sesses a wide tropism and can establish latency in the
trigeminal ganglia, lymphoid tissues, and peripheral
blood lymphocytes [17], in which they efficiently induce
both strong humoral immune and cellular immune
responses. Thus, the potential of C-KCE as a DNA-based
platform for developing polyvalent vaccine deserves
in-depth study.
Efficient genetic modification of herpesviruses, such as
DEV, has come to rely on bacterial artificial chromo-
some (BAC) for generating recombinant viruses [18]. In
this technology, a BAC-containing clone of the complete
viral genome has to be generated, enabling propagation
of the viral genome in Escherichia coli (E.coli) and avoid-
ing the need for cumbersome cloning techniques [19].
Mating-assisted genetically integrated cloning (MAGIC)
[20] utilizes bacterial mating, in vivo site-specific endo-
nuclease cleavage and homologous recombination to
catalyze the transfer of a DNA fragment between a
donor vector in one bacterial strain and recipient plas-
mid in another separate bacterial strain. The recombin-
ation between these plasmids can be forced by inducing
I-SceI to site-specific cleavage and the red-gam recom-
binase to homologous recombination. Recombination
events of MAGIC are genetically selected and result in
placement of the gene of interest under the control of
new regulatory elements with high efficiency [21].
In the present study, we established a BAC of the C-KCE
strain. The hemagglutinin (HA) gene of HPAIV H5N1 wasaccurately inserted into the C-KCE genome based on
MAGIC. A bivalent vaccine C-KCE-HA was generated by
eliminating the BAC backbone via Cre/Loxp-mediated
recombination [22]. Our data indicate that the HA
gene inserted into that C-KCE genome was robustly
expressed under the control of chicken β-actin promoter
and cytomegalovirus immediate enhancer. We further
demonstrated C-KCE-HA-immunized ducks induced
both cross-reactive antibodies and T cell response against
H5. Meanwhile this recombinant C-KCE-HA conferred
100% protection against two antigenically distinct strains
of HPAIV H5N1 and virulent DEV challenge in the duck.
Therefore, our BAC-C-KCE offers a suitable platform to
generate polyvalent live attenuated vaccine against mul-
tiple pathogens.Materials and methods
Virus strain and cells
The attenuated DEV C-KCE vaccine strain, obtained
from the China Institute of Veterinary Drugs Control,
was propagated and titrated in primary chicken embryo
fibroblasts (CEF) propagated in Eagle’s minimal essential
medium (EMEM, Biochrom), which was supplemented
with 100 μg/mL penicillin, 100 μg/mL streptomycin, and
10% fetal bovine serum (FBS) at 37 °C under a 5% CO2
atmosphere. A virulent DEV strain (HB/10) isolated from
Hubei Province in the central part of China was propa-
gated and titrated in duck embryo fibroblasts (DEF).
AIV H5N1 A/duck/Hubei/xn/2007 (H5N1) (XN/07) (clade
2.3.2) (GenBank accession number of HA: AHI43271.1)
and A/duck/Hubei/HangMei01/2006 (HM/06) (clade 2.3.4)
(GenBank accession number of HA: ACF16400.1) were
propagated in the allantoic cavities of 10-day-old specific-
pathogen-free (SPF) embryonated chicken eggs and stored
at −80 °C.Plasmids and bacterial strains
All the plasmids and E.coli strains were kindly donated
by Dr Lixin Ma. The mini-F plasmid pBlue-lox was
maintained in E.coli strain DH10B-IS2 (umuC:araC-
ParaBAD-I-Sce-I-FRT) which was constructed in Lixin
Ma’s laboratory and expresses enzyme I-SceI stimulated
by 0.2% w/v L-arabinose [21]. The plasmid pML300 con-
tained in DH10B-IS2 carries the red-gam recombinase
gene stimulated by rhamnose, and is unable to replicate
when the bacteria are grown at 42 °C [23]. DH10b was
used for generating the recombinant donor plasmid
pRThGA. DH10b, but not DH10B-IS2, provided a trans-
acting factor π, which could support the conditional origin
of replication from R6K, oriγ, which contained the
donor vector plasmid pRThGA1-HA [24]. The plasmid
pCAGGS-NLS/cre expressing Cre recombinase has been
previously described [25].
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and of donor plasmid pRThGA1-HA
The plasmid pBlue-lox-gB-UL26-Amp contains two cop-
ies of the PacI restriction site, an enhanced red fluores-
cent protein (RFP) gene and its cassette, two copies of
the direct orientation 34 bp Loxp, and two copies of the
reverse complement 18 bp I-sceI. To insert the 8.28 kb
spanning BAC mini-F plasmid into the C-KCE genome,
a 454 bp inter-genic region [15] between the gB and
UL26/UL26.5 genes was found to be suitable. The inter-
genic region is flanked by two poly A sites (Figure 1B).
The gB (UL27) is transcribed from left to right and its
poly A site is located between nucleotides 65676 and
68678, whereas the UL26/UL26.5 genes are transcribed
from right to left and their shared poly A site is located
between nucleotides 69131 and 71254 on the comple-
mentary strand. Hence, for the insertion of the BAC
plasmid sequence within the gB-UL26 junction region, a
BAC insertion plasmid containing a PacI insertion site
within the gB-UL26 inter-genic region (nucleotides 68678
to 69131) and flanked by the upstream gB gene and the
downstream UL26 gene was constructed. In brief, the gB
upstream (partial) region and the inter-genic region wereFigure 1 Generation and characterization of H5 HA gene recombinan
DEV vaccine strain (C-KCE). (B) A portion of the genome C-KCE expanded to sho
of transfer vector pBlue-lox-gB-UL26-Amp digested by PacI contains an enhanced
direct orientation 34-bp Loxp and two copies of the reverse complement 18-bp
into the genome of C-KCE with the red fluorescent protein as a selection marker
entirely replaced by the HA gene and its cassette. (F) After Cre/Loxp–mediate
positioned in C-KCE-HA genome.amplified as a 1.1 kb fragment using primers gB-F/gB-R
(Table 1). The inter-genic region and downstream UL26
(partial) region were then amplified as a 1.2 kb fragment
using primers UL26-F/UL26-R (Table 1). Briefly, the RFP
gene under the control of the immediate early promoter
of human cytomegalovirus (PHCMV) was amplified from
pRTRA as a 1.8 kb fragment using primers Red-F/Red-R
(Table 1). The three PCR products described above were
used as the templates for “a ligation PCR” using primers
UL26-F/Red-R (Table 1). A 4.3 kb fragment was then
cloned into the Sal I/Not I sites of pBlue-lox, resulting in
pBlue-lox-gB-UL26. To increase the copy number of
pBlue-lox, the ampicillin resistance gene replicon frag-
ment was amplified from pcdna3.1 (+) with the primers
Amp-F/Amp-R (Table 1), and inserted into PacI-digested
pBlue-lox-gB-UL26 to obtain the plasmid pBlue-lox-gB-
UL26-amp. Fragments from the CMV.IE enhancer to
rabbit β-globin poly A were amplified from pCAGGS
using the primers pCA-I-SceI-H1-F/pCA-I-SceI-H2-R
flanked by 50-bp homology arms and I-sceI restriction
sites. The fragment cut by I-sceI was ligated into the
pRThGA vector (also cut by the same enzymes), result-
ing in the recombinant plasmid pRThGA1. The H5t C-KCE-HA. (A) The organization of the 158-kbp attenuated commercial
w the gB, UL26 gene and inter-genic region is depicted. (C) The organization
red fluorescent protein gene and its expression cassette, two copies of the
I-sceI. (D) After homologous recombination, pBlue-lox-gB-UL26 was inserted
. (E) After MAGIC, the red fluorescent gene, CMV promoter, and ploy A were
recombination, the BAC backbone was excised only 34-bp Loxp sequence
Table 1 Primers used for generating pBAC-C-KCE, donor plasmid pRThGA and identification of the pBAC-C-KCE-HA
Purpose and primer Sequence (5’→ 3’) Sequence designation, restriction enzyme site and
introduction sequence
BAC insertiona
UL26-F aaagtcgacataacttcgtatagcatacattatacgaagttatgccgtatgaatgcgctgac Sal I site (bold), Lox p sequence (italic)
UL26-R ttaattaacgcggacaaaacgacgattac Pac I site (bold)
gB-F gtaatcgtcgttttgtccgcgttaattaatgaaaaagacggcggtacaat Pac I site (bold)
gB-R aagaatgcattcggcctgg
Red-F ccaggccgaatgcattcttcgtggggtgtggtgcttttggt
Red-R tcgagcggccgctagggataacagggtaatccccaccttatatattctttcccaccct Not I site (bold), I-isce I sequence (italic)
Amp-F aaattaattaaggggataacgcaggaaagaac Pac I site (bold)




I-isce I sequence (bold), Homology arm H1 (italic)
pCA-I-SceI-H2-R aaatagggataacagggtaattagcatgcataacttcgtataatgtatgctatacgaagt
tatgcggccgccacacaggaaacagctatgaccatgattac
I-isce I sequence (bold), Homology arm H2 (italic)
Amp t-I-SceI-F aaaattaccctgttatccctacacgttaagggattttggtcat I-isce I sequence (bold)




aPrimers used for the construction of the BAC insertion vector. The restriction are marked in italics. bPrimers used for modification of donor plasmid
pRThGA. cPrimers used for verification HA gene insertion into pBAC-C-KCE base on MAGIC.
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(H5N1) (GenBank ID: FJ784852.1) flanked by Smal I
and Xho I restriction sites synthesized by Sangon Biotech
Life Science Products & Services with several mutations at
the cleavage site as previously described [26]. The frag-
ment then was cloned into the Smal I and Xho I sites
present in pRThGA1 to generate the donor vector plas-
mid pRThGA1-HA.Construction of a C-KCE BAC clone
After C-KCE was incubated to CEF cells at a multiplicity
of infection (MOI) of 50 for 2 h at 37 °C, pBlue-lox-gB-
amp linearized with PacI (Figure 2C) was transfected by
calcium phosphate precipitation. When the complete
cytopathic effect was observed, the total supernatant
was harvested. The infected virus was diluted and then
plated on the fresh CEF, and overlaid with DMEM-FBS
containing 0.5% methylcellulose. When red fluorescent
plaques were observed, plaque-purification was carried
out as previously described [25] to obtain a fluorescent
plaque population, termed vBAC-C-KCE. Circular viral
DNA was extracted from CEF by the method of Hirt
[27]. Approximately 5 μg of genomic DNA was used to
electroporate DH10B-IS2 with 0.1 cm cuvettes under
the following conditions: 1.5 kV, resistance of 200 Ω,and capacitance of 25 μF. The plasmid pBAC-C-KCE
was isolated from chloramphenicol-resistant colonies
using QIAprep miniprep kit (Qiagen), and transfected into
CEF by the calcium phosphate precipitation method.Generating the recombinant pBAC-C-KCE-HA vector by
MAGIC and deleting the BAC vector
E. coli DH10b containing the donor vector pRThGA1-HA
was grown in LB broth containing 100 μg/mL ampicillin.
The recipient strain DH10B-IS2, containing the plas-
mid pML300 and recipient plasmid pBAC-C-KCE, was
grown in LB broth containing 50 μg/mL spectino-
mycin, 34 μg/mL chloramphenicol, 100 μg/mL strepto-
mycin, and 0.2% w/v glucose overnight. The recipient
strain was washed twice with two units of LB the next
day. The donor and recipient strains were separately
diluted to 1:25, 1:50, 1:100, or 1:200 with LB contain-
ing 0.2% w/v rhamnose, and grown at 30 °C for 2 h to
an A600 of 0.15–0.25. The donor and recipient strains
were mixed to a ratio of 1:1 based on their A600 in the
presence of 0.2% w/v L-arabinose. The mixture was in-
cubated at 37 °C for 2 h without shaking, and then for
a further 2 h with shaking. The recombinant culture was di-
luted at a ratio of 1:100, plated on selective plates containing
34 μg/mL chloramphenicol, 100 μg/mL streptomycin, and
Figure 2 Procedures for generating pBAC-C-KCE-HA base on MAGIC strategy. The donor and recipient plasmids were generated as
described in the text, then transformed into the donor strain DH10b and recipient strain DH10B-IS2. The DNA fragments of HA and its expression
cassette in the donor vector (pRTHGA-HA), and RFP and its expression cassette in the recipient vector (pBAC-C-KCE) were both cut down by an
intron-encoding rare endonuclease I-SceI induced by 0.2% w/v L-arabinose, and then the recombination events were intermediated by the red
and gam recombinase induced by 0.2% w/v rhamnose. Then, the recombinant vector pBAC-C-KCE-HA was generated.
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overnight. The positive clone was named pBAC-C-KCE-
HA. To excise the BAC vector sequence, pC-KCE-BAC–
HA was co-transfected with pCAGGS-NLS/cre into CEF.
The excised BAC vector named C-KCE-HA virus was
purified by plaque.Confirmation of the expression of the H5 HA gene in CEF
infected with the C-KCE-HA
HA protein expression in the recombinant C-KCE-HA
was evaluated by immunofluorescence (IFA) and West-
ern blot. For IFA, the CEF grown on coverslips in six-
well plates were infected at an MOI of 1 with C-KCE or
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HA (previously prepared in our laboratory) or polyclonal
antibody (pAb) against UL23 (previously prepared in our
laboratory) were used as primary antibodies. The second-
ary antibodies were fluorescein isothiocyanate-conjugated
goat anti-rabbit (for HA detection) or anti-mouse (for
UL23 detection) IgG (Santa Cruz Biotechnology, CA,
USA). The CEF nuclei were stained with 4’-6-diamidino-
2-phenylindole (DAPI). The cells were observed using laser
scanning confocal microscopy (Carl Zeiss, Zena, Germany).
The results were analyzed using software Image J (NIH,
USA). For western blot analysis, HA expression was analyzed
in CEF in six-well plates infected with C-KCE-HA and
C-KCE at an MOI of 1. mAb against HA, pAb against
UL23, and mAb against GAPDH (Santa Cruz Biotechnology,
CA, USA) for the control were used as primary antibodies.
Goat HRP-conjugated anti-rabbit or anti-mouse IgG were
used as secondary antibodies. The bands were visualized
using Electro-Chemi-Luminescence kit (Thermo, USA)
according to the manufacturer’s instructions.Stability and growth properties of the recovered virus
C-KCE-HA
To analyze the genetic stability of the foreign gene in the
recombinant virus, the virus was sequentially grown on
primary CEF for 30 passages, and viral DNA was extracted
and analyzed after each passage using HA-specific PCR
(Table 1). To compare the growth of C-KCE and C-KCE-
HA, a multi-step growth kinetic assay was performed and
the plaque sizes were measured as previously described
[28]. In order to observe the size of the plaques, the cells
were stained with crystal violet, and the plaques were
readily visible where the cells were destroyed by viral
infection.Animal experiments
SPF ducks were obtained from the Harbin Veterinary
Research Institute, China. Total of 405 one-month-old
SPF ducks were used for our studies. Six animal experi-
ments were conducted to evaluate the safety, immunogen-
icity, and protective efficacy of the C-KCE-HA vaccine
against challenge with both homologous and heterologous
HPAIV H5N1 and DEV.
For safety experiments, three groups of ducks (five per
group) were subcutaneously inoculated with 107 PFU of
C-KCE-HA (a recommended dose for DEV vaccine is
105 PFU), C-KCE, or PBS as a control.
For immunogenicity experiments against DEV, we sub-
cutaneously inoculated three groups of ducks (five per
group) with 105 PFU of C-KCE-HA, C-KCE, or PBS as a
control. At 0, 1, 2, 3, and 4 weeks post-vaccination (pv),
serum samples were obtained weekly from all ducks to
screen the neutralizing (NT) antibody against DEV.For clinical protection of C-KCE-HA against virulent
DEV challenge, three groups of ducks (twenty per group)
were inoculated subcutaneously with 105 PFU of C-KCE
or C-KCE-HA, whereas naive control ducks were inocu-
lated with PBS. Then, each groups of ducks were ran-
domly subdivided into four groups (five per group). The
ducks were challenged with a 100-fold 50% duck lethal
dose (DLD50) of HB/10 by intramuscular injection either
at 3 days, 1 week, 2 weeks, or 12 weeks pv.
To test the serological responses against HPAIV XN/
07 and HM/06 stimulated by immunized C-KCE-HA in
ducks, ducks randomly divided into three groups of ducks
(five per group) received one immunization subcutaneously
with 105 PFU of C-KCE-HA, C-KCE, or PBS as a negative
control. Serum samples were obtained weekly for 12 weeks
from all the groups to monitor the hemagglutination inhib-
ition (HI) and neutralization antibodies.
To detect the cellular response primed by immunized
C-KCE-HA in ducks, three groups of ducks (twenty per
group) were subcutaneously inoculated with C-KCE-HA
(105 PFU), C-KCE (105 PFU), or PBS (control). At 1, 4,
12, and 36 weeks pv, five ducks of each group were
sacrificed humanely. Their spleens were collected to
evaluate the cellular immune responses.
To evaluate the clinical protection of C-KCE-HA against
HPAIV XN/07, 120 ducks were randomly divided into
12 groups (ten per group). Four groups of ducks were
inoculated subcutaneously with 105 PFU of C-KCE-HA,
and eight groups were inoculated with 105 PFU of C-KCE
(four groups) or PBS (four groups) as a negative control.
Each treatment ducks were then intramuscularly chal-
lenged with a 100-fold DLD50 of XN/07 at 3 days, 1 week,
2 weeks, or 12 weeks pv. Three ducks in each group were
humanely euthanized on day 3 post-challenge (pc), and
their organs, including lung, spleen, kidney, and brain,
were collected to determine virus titration in 10-day-old
SPF embryonated chicken eggs as previously described
[29]. Oropharyngeal and cloacal swabs were collected on
days 3, 5, and 7 pc for virus titration in eggs. Ducks were
monitored daily for signs of disease and death pc for
2 weeks. The animal experimental design about evaluating
the clinical protection of C-KCE-HA against HPAIV
XM/06 is the same as the XN/07 mentioned above.
Serologic tests and virus titration
NT antibody against HB/10 was tested in DEF as previ-
ously described [12]. Serum samples were obtained to
monitor HA-specific antibodies via HI assays using chicken
red blood cells. The NT antibody against homologous
XN/07 and heterologous HM/06 of AIV was deter-
mined in MDCK cells as described previously [30]. Each
swab was washed in 1 mL of PBS with 200 μg/mL penicil-
lin and 200 μg/mL streptomycin. One gram of each organ
was collected and mixed into 1.0 mL of PBS, homogenized,
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ducted in 10-day-old SPF embryonated chicken eggs, and
calculated using the method of Reed and Muench [31].Interferon-γ (IFN-γ) ELISpot assay
Duck spleens were homogenized and washed with
Hank Balanced Salt Solution media. Gey solution was
added to remove the red blood cells. Splenocytes in
Complete Tumor Medium were added into a 96-well
(1 × 105–2 × 105 cells per well) plate pretreated with
70% ethanol and coated with anti-duck IFN-γ mAb.
Cells were re-stimulated with the HA 518 epitope con-
served in both H5N1 viruses used in this study, including
currently circulating avian and human H5N1 viruses, and
some H9N2 viruses [32]. The cultures were incubated at
37 °C and 5% CO2 for 48 h, and developed according to
an ELISpot protocol (TSZ, USA). Spots were counted
using an AID ViruSpot Reader (Cell Technology, Inc.).Statistical analysis
All experiments were reproducible and performed in
triplicate. Statistical analyses were conducted by a one-
way ANOVA test to compare the data of the difference
groups using GraphPad Prism version 5.0 (GraphPad
Software, La Jolla, CA, USA). p-values of < 0.05 were
considered statistically significant.Figure 3 Characterization of the recombinant virus BAC-C-KCE. (A) Pla
shown under green light excitation, phase contrast, or merge (400×). (B) Inve
the passages of the vBAC-C-KCE (400×). Red fluorescent protein as a selectionLaboratory facility
All experiments related to HPAIV were conducted in a
bio-security level-3 facility.Results
Establishing a full-length C-KCE clone harboring mini-F
plasmid sequences
Establishing a full-length C-KCE clone in E. coli first
requires the insertion of a BAC vector into the viral
genome (Figure 1A). Thus, the BAC vector was inserted
into a large junction of the gB and UL26 genes in the
C-KCE genome (Figure 1B). The resulting virus, vBAC-C-
KCE, was plaque-purified based on the expression of RFP
(Figure 3A). The virus was passaged in CEF for 20 rounds
to evaluate the genetic stability of the purified vBAC-C-
KCE (Figure 3B). The circular viral DNA from the vBAC-
C-KCE-infected CEF was extracted, and transformed into
the E. coli strain DH10B-IS2. pBAC-C-KCE (Figure 1D)
was isolated using a QIAprep miniprep kit and transfected
into CEF. At 5 days after transfection, approximately 90%
of the clones resulted in cytopathic effects. Two clones
were selected randomly and sequenced in Shanghai
Southgene Technology Co., Ltd. We found that one of
the two clones covered the entire 158 kb C-KCE genome
(GenBank ID: KF263690.1). Restriction fragment length
polymorphisms (RFLP) of C-KCE and BAC-C-KCE were
analyzed to confirm that a full-length C-KCE BAC cloneques of recombinant virus vBAC-C-KCE and parental virus C-KCE were
stigation of the genetic stability of vBAC-C-KCE. The numbers represent
marker was observed under fluorescence microscopy.
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pBAC-C-KCE for subsequent studies. The findings con-
firm that BAC was stably inserted into the gB and UL26
junction region in a site-specific manner.Rapid generation of the C-KCE-HA vaccine encoding
H5N1 HA
The red fluorescent gene, CMV promoter, and poly A
were entirely replaced by the HA gene and its cassette.
Thus, the HA gene was expressed under the control of
the chicken β-actin promoter. The colonies were ran-
domly selected and screened by PCR. A 1.2 kb fragment
was amplified from the positive recombinant plasmid
pBAC-C-KCE-HA (Figure 1E), and the region around the
recombination site was further confirmed by sequencing.
Among the randomly selected 24 colonies, 22 contained
the expected recombinant vector pBAC-C-KCE-HA
(Figure 4B). The efficiency of the positive clone was as
high as 90%. BAC vector sequences were flanked by
two direct orientation Loxp sequences. pBAC-C-KCE-
HA was co-transfected with pCAGGS-NLS/cre to remove
the BAC vector sequence. After Cre-mediated removal
of the BAC vector sequences, non-fluorescent plaquesFigure 4 Efficiency of HA gene insertion in pBAC-C-KCE base on MA
(A) The genome BAC-C-KCE and C-KCE were isolated and digested with Ba
that the band in line 3 are bigger than the band in line 4 (that is 8.3 kb by
weight marker (15 000-bp and 5000-bp marker, Transgen) are given. (B) De
used was DL15000. (C) Detection the expression of HA protein in C-KCE-HA
of HA protein in C-KCE-HA-infected CEF using immunofluorescence.appeared and were collected. The resulting C-KCE-HA
virus (Figure 1F) without the BAC backbone was plaque-
purified and then confirmed by PCR (data not shown).
Based on our experimental results, we found that the HA
gene could be inserted into pBAC-C-KCE via MAGIC.
Moreover, the C-KCE-HA virus, whose BAC backbone
was eliminated, was successfully generated by Cre/
Loxp–mediate recombination, and only the 34 bp Loxp
sequences were positioned in the C-KCE-HA genome.Biological characterization and stability of the rescued
C-KCE-HA recombinant viruses
To assess the genetic stability and growth kinetics of
C-KCE-HA, the virus was grown on CEF sequentially
for 30 passages. The viral DNA was extracted and ana-
lyzed after each passage using HA-specific PCR (data
not shown).
To compare the growth of C-KCE and C-KCE-HA,
the assays of multi-step growth kinetics and measure-
ments of plaque size were performed. The growth kinetics
of C-KCE-HA was similar to that of C-KCE (Additional
file 1A). The plaque sizes were also similar (Additional
file 1B). These results reveal that the HA gene was stablyGIC and characterization of the recombinant virus C-KCE-HA.
mH I and separated with a 0.8% agarose gel. The red arrowhead shows
analyzing the genome using DNAman tool). The sizes of a molecular
tection of the HA gene insertion in pBAC-C-KCE by PCR. The marker
-infected CEF by Western blotting. (D) Confirmation of the expression
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reaction on C-KCE replication in vitro. The expression of
the HA protein was determined by western blot and IFA.
As expected, the cells infected with C-KCE-HA reacted
well. Strong signals were visualized using ECL detection
reagents with mAb for HA or pAb for UL23. By contrast,
the parental virus C-KCE reacted well with mAb for
UL23, and the blank cells did not react with either of the
antibodies (Figure 4C). The results of IFA matched those
of western blot well. As shown in Figure 4D, diffused HA
and UL23 expression were observed, indicating that the
HA protein was expressed in the C-KCE-HA-infected
CEF. These results also imply that the E protein was
robustly expressed during C-KCE-HA replication.
Virulence and immunogenicity evaluation of C-KCE-HA
In our safety experiments, all the ducks remained healthy
during the observation period, demonstrating that the
insertion of the HA gene did not increase the virulence
of the vector C-KCE virus.
To evaluate whether inserting a foreign gene influ-
ences the immunogenicity of the parental virus C-KCE,
serum samples were obtained weekly for four weeks
from all ducks vaccinated with C-KCE-HA, C-KCE, or
PBS to screen the NT antibody, a marker of immuno-
genicity, against HB/10. The NT antibody titers of the
PBS-inoculated groups were lower than 3 log2 and con-
sidered negative (Additional file 2). By contrast, the NT
antibody titers of three ducks exceeded 23 in C-KCE and
C-KCE-HA vaccinated groups at one week pv. The NT
antibody titers of four ducks reached 24 at two weeks pv,
but the titers of the two groups started to drop rapidly
since then; however, they were still higher than those of
the control group (Additional file 2).
Although the NT antibody titers primed by C-KCE or
C-KCE-HA were low and short-lived, no significant dif-
ference was observed, indicating that the insertion of the
HA gene did not change the immunogenicity of the par-
ental virus C-KCE.
Clinical protection of C-KCE-HA against virulent DEV
challenge
Animal experiments were conducted to examine the effect
of the inserted exogenous gene on the protective efficacy
of the parental virus C-KCE, and evaluate the efficacy of
the C-KCE-HA vaccine against HB/10 challenge. The
ducks immunized with C-KCE or C-KCE-HA survived
the lethal challenge regardless of when they were chal-
lenged with HB/10 in our experiments. However, two
ducks that received C-KCE-HA and were challenged
on day 3 pv (Figure 5) showed slight and transient
symptoms, including polydipsia and slight loss of appetite,
at the beginning of the experimental period. Conversely,
the PBS-inoculated ducks showed severe symptoms andsuccumbed to infection within 8 days (Figure 5). The pro-
tective efficacy of C-KCE-HA and C-KCE against lethal
DEV challenge showed no difference. These results dem-
onstrate that the insertion of the HA gene did not alter
the protective efficacy of C-KCE.Induction of antibody response in C-KCE-HA-vaccinated
ducks
Antigenic drift is associated more with HA compared
with other genes [10]. The HA gene of XN/07 shares ap-
proximately 95% identity with HM/06 (Additional file 3).
The HA gene of XN/07 shares approximately 95% identity
with HM/06 (Additional file 3). To determine whether the
serological responses induced by C-KCE-HA vaccine can
cross-react with more recent H5N1 viruses isolated from
ducks, XN/07 and HM/06 were analyzed by HI and NT.
No detectable HI and NT were observed against XN/07
antigens tested in ducks that received mock vaccination
(data not shown). Tests were carried out on the sera of
C-KCE-HA-immunized ducks to detect the HI antibody
against XN/07. The earliest detection of an immune
response to XN/07 was at week 2. The antibody level
started to increase at week 3 with titers of 24 ± 22, and
it peaked at week 4 with titers of 26 ± 21. However, the
antibody level began to decline at week 5. Ultimately, the
HI antibody was not detected from any duck at 12 weeks pv
until the end of our analysis (Figure 6A). The HI antibody
responses against HM/06 were consistent with those
observed in XN/07, but the HI level was approximately
22 titers lower (Figure 6B).
Sera from vaccinated ducks were also evaluated using the
NTassay to detect functional antibodies with neutralization
activity against the XN/07 (Figure 6C) and HM/06
(Figure 6D) viruses. The trends of NT and HI antibody
responses in the C-KCE-HA-inoculated groups were
similar, but the levels of the NT antibody were higher
than those of the HI antibody at all time points tested
(Figure 6). These results demonstrate that vaccination
with C-KCE-HA induced cross-reactive antibody responses,
and primarily induced antibody responses specific to the
delivery of the HA strain.Cellular response to C-KCE-HA virus vaccination
IFN-γ ELISpot assays were performed to evaluate whether
C-KCE-HA can prime cellular immune responses. As ex-
pected, ducks that received the C-KCE-HA vaccine demon-
strated significantly increased numbers of IFN-γ-secreting
cells in spleen cells, regardless of the time the spleen cells
were stimulated with the conserved HA 518 epitope
(Figure 7). By contrast, numbers of IFN-γ-secreting
cells in the groups of C-KCE and PBS were limited.
These data demonstrate that C-KCE-HA vaccination
robustly generated cellular immune responses to HA.
Figure 5 Conferred protection from immunization of duck with C-KCE-HA vaccine against challenge with virulent DEV challenge.
Ducks were inoculated subcutaneously with 105 PFU of C-KCE-HA, 105 PFU of C-KCE or with PBS as a control, then intramuscularly challenged with
100-fold DLD50 HB/10 at 3 days (A), 1 week (B), 2 weeks (C), or 12 weeks (D) post-vaccination (pv), respectively. Ducks were monitored daily for 2 weeks
after challenge.
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ducks
To evaluate whether C-KCE-HA can induce cross-
protection against H5 AIV, we challenged the vaccinated
ducks with the homologous AIV XN/07 and heterologous
AIV HM/06. When we challenged the ducks that received
a dose of C-KCE-HA with a 100-fold DLD50 of AIV, they
were fully protected from challenge with both homolo-
gous (Table 2) and heterologous (Table 3) AIV H5N1. The
challenged virus was neither recovered from any organs
tested nor detected in the oropharynx and cloacae
(Tables 2 and 3). All the ducks remained healthy dur-
ing the observation period. In the control groups of
ducks challenged with XN/07 and HM/06 viruses,
both viruses were detected in the lung, kidney, spleen,
and brain, with titers ranging from 4.3 to 8.6 log10
50% egg infectious doses (lgEID50/g) (Additional file 4).
All the ducks shed the virus through both the oropharynx
and cloacae on day 3 and died after days 4 to 5 pc (Tables 2
and 3). These data indicate that a single dose of 105 PFU
of C-KCE-HA could induce solid cross-protection againsthomologous and heterologous H5N1 AIV challenge. Thus,
it completely blocked replication and shedding of the
challenged virus at early stages in ducks.
Discussion
Several infectious pathogens, particularly HPAIV H5N1,
can seriously threaten the progression of the duck indus-
try. Vaccines are the most effective method to control
these pathogens, and several approaches are being taken
worldwide to develop vaccines against these pathogens.
However, all of them can pose both practical and im-
munological challenges [33]. Therefore, a novel vaccine
must meet a number of criteria, including low produc-
tion cost, ease of production, high production yield, and
ease of administration. An appealing strategy for im-
proving the immunology of the virus vaccine in a prati-
cal manner involves the use of a live Anatid herpesvirus
which can deliver foreign antigens of other viruses and
can therefore serve as a dual vaccine. Thus, we estab-
lished a BAC clone of DEV attenuated strain C-KCE.
The HA gene of HPAIV H5N1 was inserted into the
Figure 6 Serological response against homologous and heterologous avian influenza virus strains in duck immunized with C-KCE-HA.
Ducks were inoculated subcutaneously with 105 PFU of C-KCE-HA. Sera were collected from ducks weekly for HI antibody and NT antibody
detection. (A). HI responses were assessed against the homologous XN/07 virus. (B). HI responses were assessed against the heterologous
HM/06 virus. (C). NT responses were assessed against the homologous XN/07 virus. (D). NT responses were assessed against the heterologous HM/
06 virus. Dotted lines indicate the thresholds for a positive response.
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contained an HA gene and its cassette, insertion exerted
no adverse effect on C-KCE replication in vitro, and it did
not alter the pathogenicity and immunogenicity of C-KCE
in vivo. After a single immunization, C-KCE-HA induced
humoral immune and cellular immune responses to HA.Figure 7 Induction of HA-518-epitope-specific and IFN-γ-secreting
spleen cells in ducks immunized with C-KCE-HA vaccine.
HA-specific responses of splenocytes taken 1, 4, 12, 36 weeks
post-vaccination as determined by IFN-γ-ELISPOT assay inducing
HA-518-epitope-specific. Data represent means standard errors
of the mean of triplicate determinations for a minimum of three
ducks per group.As early as one week pv, ducks provided solid protection
against challenge with homologous and heterologous
H5N1 virus without viral shedding, clinical signs, and
death. Therefore, the use of C-KCE-HA could simul-
taneously prevent two deadly infectious diseases, namely,
AI and DEV, with a single live virus vaccine.
Viral vectors have been widely explored for developing
vaccines. Fowlpox virus, varicella-zoster virus, pseudo-
rabies virus, turkey herpesvirus, adenovirus, baculovirus,
and Newcastle disease virus-based vectors [11,32,34-38]
are the most extensively studied viral vectors. Some re-
combinant vaccines have even been granted licenses by
some governments, and they are currently utilized for
preventing the spread of pathogens. Attenuated DEV
vaccine strains, including C-KCE and clone03, are ideal
avian vaccine vector candidates because these viruses
can induce long-lasting protection against DEV in ducks,
and they have a natural host range limited to avian
species [39].
Herpesvirus mutagenesis has come to rely on BAC
and recombinant technology to generate recombinant
viruses. Construction of the BAC of C-KCE can be used
to develop a bivalent vaccine as well as facilitate the
study of DEV pathogenesis. For example, the virulent





Vaccine Virus isolation from the swabs (shedding/total log10 EID50/mL) No. surviving/
totalDay 3 pc Day 5 pc Day 7 pc
Oropharyngeal Cloacal Oropharyngeal Cloacal Oropharyngeal Cloacal
XN/07 1 week C-KCE-HA 0/7 0/7 0/7 0/7 0/7 0/7 7/7
C-KCE 7/7(3.1 ± 0.6) 5/7(2.4 ± 0.5) — — — — 0/7
PBS 7/7(4.2 ± 0.5) 6/7(3.8 ± 0.4) — — — — 0/7
3 weeks C-KCE-HA 0/7 0/7 0/7 0/7 0/7 0/7 7/7
C-KCE 7/7(2.7 ± 0.6) 6/7(2.4 ± 0.6) — — — — 0/7
PBS 7/7(4.3 ± 0.7) 7/7(4.3 ± 0.7) — — — — 0/7
12 weeks C-KCE-HA 0/7 0/7 0/7 0/7 0/7 0/7 7/7
C-KCE 7/7(2.7 ± 0.7) 7/7(2.6 ± 1.1) — — — — 0/7
PBS 7/7(2.1 ± 0.9) 4/7(1.8 ± 1.2) — — — — 0/7
36 weeks C-KCE-HA 0/7 0/7 0/7 0/7 0/7 0/7 7/7
C-KCE 7/7(3.1 ± 0.3) 6/7(2.1 ± 0.5) — — — — 0/7
PBS 7/7(2.7 ± 0.7) 7/7(1.8 ± 0.6) — — — — 0/7
One-month-old SPF ducks were used in these studies. Groups of seven ducks were inoculated subcutaneously with 105 PFU of C-KCE-HA, 105 PFU of C-KCE or with
PBS as a control. They then were challenged intramuscularly with 100-fold DLD50 homologous (XN/07) AIVs at 1 week, 3 weeks, 12 weeks or 24 weeks
post-vaccination (pv). Oropharyngeal and cloacal swabs were collected on days 3, 5, and 7 post-challenge (pc) and titrated in SPF eggs. All of the ducks in
C-KCE and PBS groups died within 5 days. The horizontal line indicates that the animals had died by that time point.
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to evaluate the function of the gC gene [25]. Two gen-
eral approaches to infectious clone design could be ap-
plied to establish a BAC clone of the C-KCE. In one
approach, the BAC vector could be inserted into a viral
gene dispensable for viral growth and pathogenesis. In
another approach, the BAC vector was inserted into the
gene junction of the C-KCE genome. The expression of
the neighboring genes could not be interfered in this





Vaccine Virus isolation from the swabs (sh
Day 3 pc D
Oropharyngeal Cloacal O
HM/06 1 week C-KCE-HA 0/7 0/7 0
C-KCE 7/7(2.1 ± 0.9) 6/7(2.5 ± 0.3) —
PBS 7/7(3.4 ± 1.2) 7/7(3.8 ± 0.4) —
3 weeks C-KCE-HA 0/7 0/7 0
C-KCE 7/7(4.1) 7/7(3.3 ± 0.5) —
PBS 7/7(3.6 ± 0.7) 7/7(2.5 ± 1.1) —
12 weeks C-KCE-HA 0/7 0/7 0
C-KCE 7/7(2.6 ± 0.8) 7/7(3.1 ± 0.6) —
PBS 7/7(2.9 ± 0.6) 6/7(2.3 ± 1.1) —
36 weeks C-KCE-HA 0/7 0/7 0
C-KCE 7/7(2.5 ± 0.6) 5/7(2.8 ± 0.3) —
PBS 7/7(2.7 ± 0.9) 6/7(2.4 ± 0.6) —
One-month-old SPF ducks were used in these studies. Groups of seven ducks w
or with PBS as a control. They then were challenged intramuscularly with 100-fo
24 weeks post-vaccination (pv). Oropharyngeal and cloacal swabs were collecte
ducks in C-KCE and PBS groups died within 5 days. The horizontal line indicatesof DEV are available in GenBank [15,40,41]. Molecular
characterization of the genome of DEV is similar to
other herpesvirus type 1. Those areas have been proven
to be suitable for foreign gene insertion, including the
sites within gG, gB, US2, and gD [42-45]. The insertion
site of the foreign gene could alter the immunogenicity
and vaccine efficacy of recombinant DEV [39]. Hence,
we inserted a mini-F vector into the gB and UL26 gene
junction, which is the longest among all the junctions
within the C-KCE genome (454 bp). The stability ofirus HM/06 challenge in ducks
edding/total log10 EID50/mL) No. surviving/
totalay 5 pc Day 7 pc
ropharyngeal Cloacal Oropharyngeal Cloacal
/7 0/7 0/7 0/7 7/7
— — — 0/7
— — — 0/7
/7 0/7 0/7 0/7 7/7
— — — 0/7
— — — 0/7
/7 0/7 0/7 0/7 7/7
— — — 0/7
— — — 0/7
/7 0/7 0/7 0/7 7/7
— — — 0/7
— — — 0/7
ere inoculated subcutaneously with 105 PFU of C-KCE-HA, 105 PFU of C-KCE
ld DLD50 heterologous (HM/06) AIVs at 1 week, 3 weeks, 12 weeks or
d on days 3, 5, and 7 post-challenge (pc) and titrated in SPF eggs. All of the
that the animals had died by that time point.
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which was serial passaged 20 times, in CEF. This finding
indicates that the junction of C-KCE was an ideal loca-
tion for foreign gene insertion.
We accurately and efficiently inserted the HA gene
into pBAC-C-KCE via MAGIC. Notably, the efficiency
of the positive clone was approximately 90%. MAGIC
has been explored in many viruses, such as adenoviruses
and baculovirus [21,46]. In contrast to other traditional
systems, this novel strategy is highly efficient, time-
efficient, and uses a low level of background nonrecom-
binants to construct a recombinant virus. The vaccine
strains for AI control have been frequently updated; AIV
have undergone rapid genetic evolution, and expanded
their host range and virulent properties in mammals
[12]. Thus, BAC-C-KCE based on MAGIC could be con-
sidered for the development of the AI vaccine against
newly emerging AIV in ducks. Once the HA sequence of
an emerging AIV is known, a bivalent vaccine can be
rapidly generated. For example, the recent emergence of
the AIV (H7N9) strain in poultry and its subsequent
transmission to humans in China have raised great
concerns about the potential pandemic spread of lethal
diseases [47]. Utilizing MAGIC, we successfully con-
structed and obtained the recombinant vaccine expression
of HA of H7N9 within two weeks of acquiring the HA gene
(data not shown).
Generally, the expression level has two important deter-
minants, including the inserted gene itself and its promoter.
Previous studies have demonstrated that the expression of
HA in the pCAGGS vector can display higher levels than
that in other vectors [11,15]. We reasoned that the amount
of HA expression was critical to the efficacy of C-KCE-HA
for inducing protective neutralization antibodies against
AIV. To this end, we also selected the chicken β-actin
promoter driving a high-level of protein expression
across a wide range of species and cell types. Indeed,
our results show that HA protein was robustly expressed
during C-KCE-E replication, and the protection efficiency
of C-KCE-HA also improved [39].
The neutralization antibody against influenza virus is
the hallmark of protective immunity [32]. Serological
data revealed that the antibodies could be barely de-
tected at 1 and 12 weeks pv. Of note, our challenge stud-
ies showed that the C-KCE-HA provided protection
from a lethal challenge with homologous virus XN/07
and early isolate HM/06, which is antigenically different.
Thus, in addition to neutralizing, antibodies play a role
in this protection but T-cell responses, which have been
shown to aid in virus clearance, also contribute to this
protection [32]. Clearly, the HA protein is the major surface
glycoprotein of the influenza virus; it not only induces
HA-specific antibodies, but also stimulates cellular re-
sponses [36]. Our study builds upon these findings,going one step further in trying to understand the role of
the T-cell response to the C-KCE-HA influenza virus HA
vaccine. The presence of heterotypic H5N1 protection
without a sufficient humoral neutralizing response, further
reinforced by the ability of the C-KCE-HA vaccine to fully
protect the immunized duck, strongly suggests a com-
plementary role for the cellular response to its humoral
counterpart. Moreover, the provision of long-term immun-
ity with a single dose of C-KCE-HA had obvious benefits
to layers and breeder flocks [39]. Overall, the C-KCE-based
vaccine could be utilized to offset traditional inactivated
AIV vaccines.
Our findings highlight the potential of a BAC-C-KCE-
vector-based delivery system, which offers stockpiling
options for the development of a pandemic influenza
vaccine. In addition to insertion of HA alone, due to the
huge capacity of the BAC system, viral NP and M2 can
be inserted to generate a universal influenza vaccine [48]
against newly emerging antigenic drift and shift variants.
Similarly, immunogenic genes of other pathogens, such
as duck hepatitis virus, duck tembusu virus, and AIV
H9N2, could also be inserted at the same time to gener-
ate a polyvalent vaccine. We expect that the application
of this novel BAC-C-KCE platform to develop a series of
vaccines in the near future will greatly decrease those
pathogens in poultry.Additional files
Additional file 1: Comparsion of the growth between C-KCE and
C-KCE-HA. (A). Multi-step growth kinetics of C-KCE-HA and C-KCE in
CEF cells. Data were shown for the indicated time points after infection
with an MOI of 0.01. Titers are given as plaque forming units in 0.1 mL.
Means of virus titers as determined by three independent experiments are
shown; standard deviations are shown with the error bars. (B). Plaque
phenotype of C-KCE-HA and C-KCE in CEF cells. After titration of viruses, cells
were fixed in 4% paraformaldehyde and stained with crystal violet.
Additional file 2: Humoral immune response against virulent DEV
in ducks vaccinated with C-KCE-HA or its parental strain C-KCE.
Groups of 5 ducks were inoculated subcutaneously with 105 PFU of
C-KCE-HA, C-KCE or with PBS as a control. Sera were collected range
from 0 to 4 weeks to detect the NT antibody against virulent DEV in
DEF cells. NT antibody titers for ducks are expressed as a log2. Dotted
lines indicate the thresholds for a positive response.
Additional file 3: Phylogenetic relationships of the HA genes of
H5N1 AIV. The tree includes AIV that were isolated from some provinces
in China during 2004 to 2010. The phylogenetic tree was generated with
the MEGA (version 5.0) by using the neighbor-joining algorithm and
based on bootstrap values of 1000. The HA gene donor virus for the
recombinant vaccine generation and the challenge viruses used in this
study are marked in red.
Additional file 4: Replication of challenge virus in ducks.
Homologous and heterologous H5N1 replication in the organs of ducks
that were vaccinated with C-KCE-HA. Groups of three ducks were inoculated
subcutaneously with 105 PFU of C-KCE-HA, C-KCE or with PBS as a control.
They then were challenged with homologous (XN/07) or heterologous
(HM/06) AIV intramuscularly at 1 week, 3 weeks, 12 weeks or 36 weeks pv.
Day 3 after challenge, the ducks were euthanized and their organs were
harvested for virus titration in eggs. Data represent means ± standard
Zou et al. Veterinary Research  (2015) 46:42 Page 14 of 15deviations of log10 EID50s. The backslash indicates that the challenge virus
was not detected by that time point.
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